NASDAQ$OABI
OmniAb Inc · Q2 2025 earnings
Q2 2025 earnings · · After market close · Investor relations
Briefing
OmniAb Inc reported financial results for the second quarter ended June 30, 2025.
OmniAb reported total revenue of $3.9 million for Q2 2025, down from $7.6 million in the prior year quarter, driven by lower license, service and royalty revenue. The company posted a net loss of $15.9 million and an operating loss of $16.2 million. Active partners increased to 100 with 381 active programs and 32 active clinical programs and approved products.
- Total revenue declined 49% year-over-year to $3.9 million, primarily due to lower license and milestone, service, and royalty revenue.
- Net loss widened to $15.9 million from $13.6 million in Q2 2024, with operating expenses of $20.1 million.
- Ended the quarter with $18.3 million in cash and cash equivalents and $295.7 million in total assets.
- Platform metrics showed growth to 100 active partners, 381 active programs, and 32 active clinical programs and approved products.
Headline financials
Revenue & EPS history
OmniAb · Revenue · Quarterly
$3.9M
Revenue by segment
OmniAb · $3.9M total across 4 segments · Q2 2025
- Service revenue$1.94M—49.7%
- License and milestone revenue$1.24M—31.9%
- xPloration revenue$608K—15.6%
- Royalty revenue$111K—2.8%
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 17 quarterly earnings reports
-2.1%
Avg return
Earnings day
+1.5%
Avg return
5 days after
+4.1%
Avg return
30 days after
39%
7 / 18 earnings
Positive
+9.9%
Q4 2025
Best reaction
-20.4%
Q4 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2026 | +2.1% | +29.4% | +72.7% | |
| Q4 2025 | +9.9% | +9.9% | -14.9% | |
| Q3 2025 | -4.1% | +0.7% | +31.8% | |
| Q1 2025 | -7.2% | -3.2% | -4.5% | |
| Q4 2024 | -20.4% | -20.4% | -43.9% | |
| Q3 2024 | -11.5% | -15.7% | -13.0% | |
| Q2 2024 | +4.4% | +4.9% | -2.2% | |
| Q1 2024 | +3.1% | -0.9% | +2.2% | |
| Q4 2023 | -2.5% | +0.8% | -11.4% | |
| Q3 2023 | -6.8% | +3.5% | +7.3% | |
| Q2 2023 | -5.7% | -3.8% | -10.4% | |
| Q1 2023 | +6.1% | +16.1% | +37.3% | |
| Q4 2022 | +9.5% | +10.1% | +3.6% | |
| Q3 2022 | -15.5% | -4.1% | +19.3% | |
| Q2 2022 | +0.2% | +0.1% | +0.3% | |
| Q1 2022 | -0.0% | +0.0% | +0.1% | |
| Q4 2021 | -0.0% | -0.1% | -0.1% | |
| Q3 2021 | +0.0% | +0.0% | -0.1% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro